Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q5VVX9

UPID:
UBE2U_HUMAN

ALTERNATIVE NAMES:
E2 ubiquitin-conjugating enzyme U; Ubiquitin carrier protein U; Ubiquitin-protein ligase U

ALTERNATIVE UPACC:
Q5VVX9; Q8N1D4

BACKGROUND:
Ubiquitin-conjugating enzyme E2 U, known for its roles as E2 ubiquitin-conjugating enzyme U, Ubiquitin carrier protein U, and Ubiquitin-protein ligase U, catalyzes the critical step of ubiquitin attachment to substrates. This enzymatic activity is essential for the ubiquitin-proteasome system, which regulates protein turnover and signaling pathways.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Ubiquitin-conjugating enzyme E2 U offers a promising avenue for the development of novel therapeutic approaches. By targeting this enzyme, researchers aim to influence the ubiquitin-proteasome system, potentially leading to breakthroughs in the treatment of diseases where protein homeostasis is disrupted.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.